HC Wainwright Expects Lower Earnings for Stoke Therapeutics

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright dropped their FY2029 earnings per share estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, November 5th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of $0.35 for the year, down from their prior forecast of $0.46. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

STOK has been the subject of a number of other reports. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday. BTIG Research reiterated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Wedbush lifted their target price on Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. upped their price target on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday. Finally, Jefferies Financial Group began coverage on Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $31.00.

Stoke Therapeutics Trading Down 1.5%

Shares of Stoke Therapeutics stock opened at $22.47 on Thursday. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $38.69. The company’s fifty day simple moving average is $26.40 and its 200-day simple moving average is $17.07. The company has a market cap of $1.28 billion, a price-to-earnings ratio of 33.54 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 14,922 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total transaction of $300,529.08. Following the completion of the transaction, the general counsel owned 18,176 shares in the company, valued at $366,064.64. This trade represents a 45.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Md Kaye sold 45,996 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total value of $925,899.48. Following the completion of the sale, the director owned 91,585 shares in the company, valued at approximately $1,843,606.05. This represents a 33.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 186,607 shares of company stock worth $4,224,210 over the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. Kennondale Capital Management LLC bought a new position in shares of Stoke Therapeutics during the first quarter valued at $280,000. Dauntless Investment Group LLC bought a new stake in shares of Stoke Therapeutics in the 1st quarter worth about $190,000. XTX Topco Ltd acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth about $267,000. US Bancorp DE lifted its holdings in Stoke Therapeutics by 9,743.9% during the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after purchasing an additional 11,108 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Stoke Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock valued at $18,515,000 after purchasing an additional 53,004 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.